文献速递复苏、休克与脓毒症心脑血管急症消化、代谢与肾脏急症

固定剂量与可变剂量四因子凝血酶原复合物在抗凝相关大出血中的效果比较

Evaluating the use of fixed versus variable dosing of 4-factor prothrombin complex concentrate in anticoagulant-related major bleeding.
PubMed 文献 · Am J Emerg Med · 2025-10-10
一句话结论固定剂量四因子凝血酶原复合物在抗凝相关大出血中止血效果与可变剂量相当,且平均费用显著更低。

本研究为单中心回顾性队列研究,纳入2018年1月1日至2023年8月31日接受四因子凝血酶原复合物(4F-PCC)治疗的患者,比较固定剂量与可变剂量在维生素K拮抗剂(VKA)和口服Xa因子抑制剂相关大出血中的止血效果。主要终点有效止血率固定剂量组57% vs 可变剂量组53%(风险差3.7%,95%CI -14.5至22.0)。7天内血栓栓塞事件发生率固定剂量组4.2% vs 可变剂量组10.6%(风险差6.4%,95%CI -16.4至3.5)。4F-PCC平均费用固定剂量组7023美元 vs 可变剂量组11311美元,组间差异4288美元(95%CI 3150至5425)。结论认为固定剂量4F-PCC止血效果与可变剂量相当,且总费用显著更低。

要点

  • 在VKA和口服Xa因子抑制剂相关大出血中,固定剂量4F-PCC有效止血率为57%,可变剂量组为53%(风险差3.7%,95%CI -14.5至22.0)。
  • 固定剂量组7天内血栓栓塞事件发生率为4.2%,可变剂量组为10.6%(风险差6.4%,95%CI -16.4至3.5),未达统计学显著。
  • 固定剂量4F-PCC平均费用为7023美元,可变剂量组为11311美元,组间差异4288美元(95%CI 3150至5425)。
  • 上述结果在所有类型和严重程度的抗凝相关大出血中保持一致。
  • 本研究为单中心回顾性队列研究,固定剂量4F-PCC在止血效果上与可变剂量相当,且总费用显著更低。

适用人群与场景

  • 接受4F-PCC治疗的VKA或口服Xa因子抑制剂相关大出血患者,包括胃肠道出血和颅内出血(ICH),以及需要紧急外科干预者。
  • 研究纳入2018年1月1日至2023年8月31日期间接受4F-PCC的患者。

诊断标准与关键阈值

  • 有效止血依据国际血栓与止血学会(ISTH)定义。

研究设计与关键结果

  • 单中心回顾性队列研究,比较固定剂量与可变剂量4F-PCC在VKA和FXa相关大出血中的止血效果。
  • 主要终点有效止血率:固定剂量组57% vs 可变剂量组53%(风险差3.7%,95%CI -14.5至22.0)。
  • 7天内血栓栓塞事件:固定剂量组4.2% vs 可变剂量组10.6%(风险差6.4%,95%CI -16.4至3.5)。
  • 4F-PCC平均费用:固定剂量组7023美元 vs 可变剂量组11311美元,组间差异4288美元(95%CI 3150至5425)。
  • 结果在所有类型和严重程度的抗凝相关大出血中保持一致。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,固定剂量4F-PCC在VKA和FXa相关大出血中止血效果与可变剂量相当,且总费用显著更低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: 4-factor prothrombin complex concentrate (4F-PCC) is used for reversal of vitamin K antagonists (VKA) and oral factor Xa (FXa) inhibitors in patients with major bleeding, including gastrointestinal bleeding and intracranial hemorrhage (ICH), and in those requiring emergent surgical intervention. Fixed dose 4F-PCC may offer the advantage of decreased cost and simplified administration. The objective of this study was to evaluate the effectiveness of fixed dose versus variable dose 4F-PCC in the achievement of hemostasis in VKA and FXa-associated major bleeding.

METHODS: Single-center, retrospective cohort study of patients who received 4F-PCC from January 1, 2018 through August 31, 2023. The primary outcome of effective hemostasis was based on the International Society on Thrombosis and Hemostasis definition.

RESULTS: Overall, baseline characteristics were similar between groups. The primary endpoint of effective hemostasis was achieved by 57 % of patients in the fixed dose group and 53 % of patients in the variable dose group (Risk difference [RD] 3.7 %, 95 % CI -14.5 to 22.0). The incidence of thromboembolic events within 7 days of 4F-PCC was lower in the fixed dose group compared with the variable dose group, at 4.2 % and 10.6 %, respectively (RD 6.4 %, 95 % CI -16.4 to 3.5). The average cost of 4F-PCC was $7023 in the fixed dose group versus $11,311 in the variable dose group with a between-group difference of $4288 (95 % CI 3150 to 5425). These results were consistent across all types and severities of anticoagulant-associated major bleeding.

CONCLUSIONS: In this study, fixed dose 4F-PCC was as effective as variable dose 4F-PCC in the achievement of hemostatic efficacy for VKA and FXa-associated major bleeding with a significantly lower overall cost.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Schrader E, Zinser B, Kulhari A, et al. Evaluating the use of fixed versus variable dosing of 4-factor prothrombin complex concentrate in anticoagulant-related major bleeding. Am J Emerg Med. 2025. PMID: 41106151. doi:10.1016/j.ajem.2025.10.019

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。